化学学报 ›› 2024, Vol. 82 ›› Issue (7): 772-781.DOI: 10.6023/A24030085 上一篇    下一篇

研究论文

金属离子-吉西他滨单磷酸酯络合物纳米粒用于胰腺癌治疗的研究

罗倩钰a, 汪诚艳c, 张天龙a, 夏培元c, 张潇c,*(), 杨明b,*()   

  1. a 川北医学院药学院 南充 637000
    b 川北医学院附属医院药剂科 南充 637000
    c 陆军军医大学第一附属医院 重庆 400038
  • 投稿日期:2024-03-14 发布日期:2024-06-04
  • 基金资助:
    重庆市博士“直通车”科研项目(CSTB2022BSXM-JCX0127); 重庆英才计划创新领军人才(425Z2P12D)

Metal Ion-gemcitabine Monophosphate Nanoparticles for Effective Treatment of Pancreatic Cancer

Qianyu Luoa, Chengyan Wangc, Tianlong Zhanga, Peiyuan Xiac, Xiao Zhangc,*(), Ming Yangb,*()   

  1. a School of Pharmacy, North Sichuan Medical College, Nanchong 637000, China
    b Department of Pharmacy, the Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China
    c The First Affiliated Hospital of Army Medical University, Chongqing 400038, China
  • Received:2024-03-14 Published:2024-06-04
  • Contact: *E-mail: zhangxiao_swh@163.com;yangming1211@nsmc.edu.cn
  • Supported by:
    Chongqing Doctoral Research Project(CSTB2022BSXM-JCX0127); Innovation Leading Talents of Chongqing Talent Program(425Z2P12D)

本研究旨在构建多种金属离子与吉西他滨单磷酸酯(GMP)络合形成的纳米粒, 考察该系列纳米粒的体外抗肿瘤活性, 并筛选出抗肿瘤活性最佳的金属药物复合纳米粒, 同时对该纳米粒中金属元素的协同机理进行研究. 首先, 采用反相微乳法制备出多种金属离子-吉西他滨单磷酸酯络合物纳米粒(Metal-GMP NPs). 随即, 通过动态光散射法对纳米粒的水合粒径、多分散系数和电位进行测定; 通过高效液相色谱(HPLC)以及电感耦合等离子体质谱仪(ICP-MS)测定纳米粒中GMP和金属元素的含量, 进而确定Metal-GMP NPs中GMP的包封率、载药率及GMP与金属的物质的量比; 通过场发射透射电镜观察纳米颗粒形貌. 然后, 通过CCK8法研究Metal-GMP NPs对不同胰腺癌细胞系的增殖抑制作用, 筛选出了抗肿瘤活性最佳的Fe-GMP NPs, 并通过流式细胞技术、蛋白免疫印迹法等验证Fe-GMP NPs中的铁离子对GMP的协同作用机制. 结果表明Fe-GMP NPs可通过消耗细胞内的谷胱甘肽(GSH)产生游离的二价铁离子, 诱导肿瘤细胞内发生芬顿反应, 催化生成高细胞毒性的活性氧(ROS), 打破肿瘤细胞内的氧化还原稳态, 实现金属铁协同GMP化疗的效果. 最后, 在动物模型上验证Fe-GMP NPs的治疗效果和安全性. 本研究成功构建了一系列具有抗肿瘤活性的金属-吉西他滨单磷酸酯络合物纳米粒, 从中筛选出了效果最佳的Fe-GMP NPs, 并进行药效与机制研究, 为吉西他滨治疗胰腺癌提供新的研究思路.

关键词: 吉西他滨单磷酸酯, 金属离子, 纳米粒, 胰腺癌, 协同化疗

Gemcitabine is the first-line chemotherapeutic agent and the gold standard for pancreatic cancer. However, the short blood half-life and drug resistance limit its therapeutic efficacy in clinic. Recent advancements in nanotechnology offered a potent approach for improving gemcitabine delivery and efficacy. In this study, we present the design and synthesis of gemcitabine-loaded nanoparticles utilizing gemcitabine monophosphate (GMP) and metal ions via a coordination-precipitation strategy. Firstly, a series of metal ions, including Ca2+, Fe3+, Mn2+, Gd3+ and Lu3+, were mixed with GMP to form nanoparticles (Metal-GMP NPs) employing a reverse-phase microemulsion method. The morphology of the as-prepared Metal-GMP NPs were characterized by transmission electron microscopy while the hydrated particle size, polydispersion index and zeta potential were measured by dynamic light scattering. Additionally, the encapsulation efficiency and loading ratio of GMP, as well as the molar ratio of GMP to metals were quantified through high performance liquid chromatography (HPLC) and inductively coupled plasma mass spectrometry (ICP-MS). Subsequently, the anti-tumor efficacy of the as-prepared Metal-GMP NPs were studied by CCK8 assay on three different pancreatic cancer cell lines. The screening results suggested that Fe-GMP NPs has the preferable anti-tumor activity as well as the obvious synergistic effect between metal ions and drugs. The further mechanism studies revealed that Fe-GMP NPs could generate enough cytotoxic reactive oxygen species (ROS) through Fenton-like reactions within tumor cells. And simultaneously, the intracellular reduced glutathione (GSH) was consumed, thereby disrupting the redox homeostasis and enhancing GEM efficacy. Finally, the therapeutic efficacy and bio-safety of Fe-GMP NPs were investigated on the subcutaneous tumor-bearing model. The in vivo results demonstrated that Fe-GMP NPs exhibited better therapeutic efficacy rather than GMP free drugs alone. Meanwhile, the bio-safety assessment confirmed the absence of significant toxicity or side effects associated with Fe-GMP NP treatment. This work combines metal ions with gemcitabine in the manner of chemistry, providing a highly promising strategy for the delivery and sensitization of gemcitabine in pancreatic cancer therapy.

Key words: gemcitabine monophosphate, metal ion, nanoparticle, pancreatic cancer, synergistic chemotherapy